Anzeige
Meldung des Tages: Rüstungsindustrie unter Druck: Warum ein seltenes Metall plötzlich zum Milliardenfaktor wird

Roche Holding News

Aktie
WKN:  851311 ISIN:  CH0012032113 US-Symbol:  RHHBF Branche:  Pharmazeutika Land:  Schweiz
346,00 CHF
+1,80 CHF
+0,52%
382,47 € 17:19:47 Uhr
Depot/Watchlist
Marktkapitalisierung *
250,27 Mrd. €
Streubesitz
17,13%
KGV
25,93
Dividende
10,22 EUR
Dividendenrendite
2,83%
Nachhaltigkeits-Score
59 %
Index-Zuordnung
-

Roche Holding News

14:15 Uhr - GlobeNewswire
Roche Annual General Meeting 2026
Shareholders approved all proposals of the Board of Directors  Severin Schwan re-​elected as Chairman of the Board of Directors; all other Board members standing for election ...
14:15 Uhr - GlobeNewswire
Roche Generalversammlung 2026
Alle Anträge des Verwaltungsrates genehmigt Severin Schwan erneut als Präsident des Verwaltungsrates gewählt; alle weiteren zur Wahl stehenden Verwaltungsrätinnen und ...
09.03.26 - GlobeNewswire
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase III persevERA study in ER-positive advanced breast cancer
persevERA Breast Cancer study did not meet the primary objective of a statistically significant improvement in progression-​free survival, but a numerical improvement was observed  ...
07.03.26 - ARIVA.DE Redaktion
Schock für Anleger: Zealand-Aktie bricht ein – enttäuschende Studiendaten im Milliardenmarkt für Abnehmmedikamente
Mehr als 30 Prozent Kursverlust an nur einem Tag und 1,3 Milliarden US-Dollar Marktkapitalisierung futsch: Schwächere Studiendaten zum Adipositas-​Medikament Petrelintid ...
06.03.26 - GlobeNewswire
New England Journal of Medicine publishes phase III ALLEGORY data showing Roche’s Gazyva/Gazyvaro significantly reduces disease activity in the most common form of lupus
Over three quarters of people on Gazyva/Gazyvaro plus standard therapy achieved at least a four-​point improvement in SRI-4, a measure that assesses disease severity and ...
05.03.26 - GlobeNewswire
Roche announces positive Phase II results for petrelintide, an amylin analog developed for people living with overweight and obesity
Petrelintide achieved up to 10.7% mean body weight reduction at week 42 versus 1.7% with placebo (p-value At the maximally effective dose, there were no cases of vomiting and no ...
02.03.26 - GlobeNewswire
[Ad hoc announcement pursuant to Art. 53 LR] Roche's fenebrutinib confirms its potential as first and only BTK inhibitor for relapsing and primary progressive MS in third positive Phase III study (FENhance 1)
FENhance 1 met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses by 51% compared to teriflunomide in relapsing multiple sclerosis (RMS), ...
20.02.26 - GlobeNewswire
FDA accepts New Drug Application for Roche’s giredestrant in ESR1-mutated, ER-positive advanced breast cancer
Filing acceptance based on phase III data showing giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and  ESR1 -mutated ...
17.02.26 - IT-Times
Change to the Roche Enlarged Corporate Executive Committee
17.02.26 - GlobeNewswire
Change to the Roche Enlarged Corporate Executive Committee
Basel, 17 February 2026 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the appointment of Mark Dawson, M.D., Ph.D., as the new Head of Roche Pharma Research ...
16.02.26 - IT-Times
Roche announces positive phase III results for Gazyva/Gazyvaro in primary membranous nephropathy, marking a significant milestone in this autoimmune disease
16.02.26 - GlobeNewswire
Roche announces positive phase III results for Gazyva/Gazyvaro in primary membranous nephropathy, marking a significant milestone in this autoimmune disease
MAJESTY, the first global phase III study in primary membranous nephropathy, met its primary endpoint of complete remission at two years Up to 30% of people with membranous ...
07.02.26 - GlobeNewswire
Roche’s fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS)
Late-​breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of non-​inferiority compared to the current standard of ...
29.01.26 - GlobeNewswire
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2025 results with 7% sales growth
Group sales grew by 7% 1 at constant exchange rates (CER; 2% in CHF), driven by strong demand for medicines and diagnostic solutions. Sales in the fourth quarter increased by ...
29.01.26 - GlobeNewswire
[Ad-hoc-Mitteilung gemäss Art. 53 KR] Roche erzielt starkes Jahresergebnis für 2025 mit Verkaufswachstum von 7%
Konzernverkäufe stiegen um 7% 1 zu konstanten Wechselkursen (CER; 2% in CHF) dank hoher Nachfrage nach Medikamenten und diagnostischen Lösungen. Im vierten Quartal ...
27.01.26 - GlobeNewswire
[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase II results for its dual GLP-1/GIP receptor agonist CT-388 in people living with obesity
A once-​weekly subcutaneous injection of CT-388 achieved a statistically significant placebo-​adjusted weight loss of 22.5% (p 54% of participants on the 24 mg dose achieved ...
22.12.25 - Maximilian Berger
ROCHE HOLDING AG GS steht still – ich rieche Bewegung!
Die Roche-​Aktie (WKN 855167) zeigt sich robust. Was Anleger zur aktuellen Kursentwicklung, Bewertung und Zukunftschancen wissen sollten.
22.12.25 - GlobeNewswire
FDA approves Roche’s Lunsumio VELO™ for subcutaneous use in relapsed or refractory follicular lymphoma
Lunsumio VELO reduces administration time from 2-4 hours to approximately one minute Availability of Lunsumio VELO allows treatment aligned to people’s clinical needs and ...
11.12.25 - GlobeNewswire
Roche expands automated mass spectrometry menu with antibiotics drug monitoring CE mark approval offering industry’s broadest in vitro diagnostic menu
With this approval, Roche’s automated mass spectrometry platform now offers the industry’s broadest in vitro diagnostic menu with 39 tests, including tests for therapeutic drug ...
10.12.25 - GlobeNewswire
Roche’s giredestrant reduced risk of invasive disease recurrence or death by 30% in ER-positive early-stage breast cancer
Giredestrant is the only oral SERD to show superior invasive disease-​free survival in the adjuvant setting, marking the first significant endocrine therapy advance in over 20 years 1-3 ...

Newssuche

Videos

newspaper
10:40 Uhr +58,73%
Technical Trading: DAX Long Chance
DAX Long Typ: Turbo Open End WKN: VK2CGA Hebel:11,30 Laufzeit: OpenEnd Einstieg: Market ... Mehr »